Peer Review History

Original SubmissionSeptember 2, 2022
Decision Letter - Jaimin R. Trivedi, Editor

PONE-D-22-23111Partial Heart Transplantation for Severe Pediatric Semilunar Valve Dysfunction: A Clinical Trial ProtocolPLOS ONE

Dear Dr. Zilinskas,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Nov 19 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.
  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.
  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

Jaimin R. Trivedi, MBBS, MPH

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Thank you for stating the following financial disclosure: 

"The funders had and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

At this time, please address the following queries:

a) Please clarify the sources of funding (financial or material support) for your study. List the grants or organizations that supported your study, including funding received from your institution. 

b) State what role the funders took in the study. If the funders had no role in your study, please state: “The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.”

c) If any authors received a salary from any of your funders, please state which authors and which funders.

d) If you did not receive any funding for this study, please state: “The authors received no specific funding for this work.”

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

3. Thank you for stating the following in the Funding Section of your manuscript: 

"BG and JK are funded by NIH-NHLBI Institutional Postdoctoral Training Grants (T32 HL-007260). TKR is funded by the American Association for Thoracic Surgery, the Children's Excellence Fund held by the Department of Pediatrics at the Medical University of South Carolina, the Brett Boyer Foundation, and the Emerson Heart Foundation."

We note that you have provided funding information that is not currently declared in your Funding Statement. However, funding information should not appear in the Funding section or other areas of your manuscript. We will only publish funding information present in the Funding Statement section of the online submission form. 

Please remove any funding-related text from the manuscript and let us know how you would like to update your Funding Statement. Currently, your Funding Statement reads as follows: 

"The funders had and will not have a role in study design, data collection and analysis, decision to publish, or preparation of the manuscript."

Please include your amended statements within your cover letter; we will change the online submission form on your behalf.

4. We note that the original protocol that you have uploaded as a Supporting Information file contains an institutional logo. As this logo is likely copyrighted, we ask that you please remove it from this file and upload an updated version upon resubmission.

Additional Editor Comments (if provided):

The manuscript has been reviewed by independent reviewers including a statistical reviewer. They have raised some important points including certain ethical considerations and statistical/study design suggestions. Please carefully consider their comments and suggestions.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions?

The research question outlined is expected to address a valid academic problem or topic and contribute to the base of knowledge in the field.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses?

The manuscript should describe the methods in sufficient detail to prevent undisclosed flexibility in the experimental procedure or analysis pipeline, including sufficient outcome-neutral conditions (e.g. necessary controls, absence of floor or ceiling effects) to test the proposed hypotheses and a statistical power analysis where applicable. As there may be aspects of the methodology and analysis which can only be refined once the work is undertaken, authors should outline potential assumptions and explicitly describe what aspects of the proposed analyses, if any, are exploratory.

Reviewer #1: Yes

Reviewer #2: Partly

**********

3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable?

Descriptions of methods and materials in the protocol should be reported in sufficient detail for another researcher to reproduce all experiments and analyses. The protocol should describe the appropriate controls, sample size calculations, and replication needed to ensure that the data are robust and reproducible.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors described where all data underlying the findings will be made available when the study is complete?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception, at the time of publication. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: No

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics.

You may also provide optional suggestions and comments to authors that they might find helpful in planning their study.

(Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Ochoa and colleagues describe a protocol for a prospective nonrandomized, single-center, single arm pilot trial where a “partial heart transplant” will be performed in infants and young children with semilunar valve disease. The hypothesis is that the transplant semilunar valves will grow with the patient and avoid known complications associated with current valve options for these children. This a reasonable protocol, however, I have following specific comments for the authors

“Inability for the parent(s) or legal guardian(s) to understand English or Spanish”, this seems like an inappropriate exclusion criterion, especially when all study procedures are standard clinical care, and one would expect that inability to understand these languages does not preclude clinical care.

There is another ethical issue/potential risk with this procedure that is not discussed. A potential organ for life-saving heart transplant is diverted for a treatment that has other surgical options. This should be discussed and potentially be part of the informed consent. Furthermore, donor selection is not discussed in detail, could these donors have suboptimal cardiac function and not suitable for conventional heart transplant?

It may be after this submission, but there has been a clinical case described as “first partial heart transplant” from Duke University in the news lately. Citation of that would be important for complete reference of prior work.

Lower levels of immunosuppression are proposed as a possibility after first year, a description of such protocol is important for completeness.

Reviewer #2: This study addresses an interesting topic. It is well detailed and may lead to interesting results. Some comments follow.

1. The sample size is rather small. It is necessary to specify the power of the study. Similarly, the fact that it is a nonrandomized single-center study may strongly limit its practical usefulness. Indeed, my main concern is about how general the obtained results would be. It is difficult to understand why such a small sample size is aimed to be collected.

2. Missing data management needs a better discussion. Missing data could be completely-at-random, at-random, not-at-random. Sensitivity analysis should be planned to avoid misleading inference whenever complete-case analysis is performed.

3. The data analysis is based on descriptive statistics only. This strongly limits the project. If research questions cannot be tested, if inference cannot be performed, the study simply describes a specific sample, that may not be representative of a larger population. Which general info do you expect to get from a simple descriptive analysis? Cause-effect relationships cannot be investigated, nor any characterization of the outcomes could be discussed. The data analysis is not sufficient to provide informative results. I strongly suggest to plan a more detailed and extensive statistical analysis, based on a larger sample. Statistical inference must be guranteed.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

Revision 1

Reviewer #1: Ochoa and colleagues describe a protocol for a prospective nonrandomized, single-center, single arm pilot trial where a “partial heart transplant” will be performed in infants and young children with semilunar valve disease. The hypothesis is that the transplant semilunar valves will grow with the patient and avoid known complications associated with current valve options for these children. This a reasonable protocol, however, I have following specific comments for the authors

“Inability for the parent(s) or legal guardian(s) to understand English or Spanish”, this seems like an inappropriate exclusion criterion, especially when all study procedures are standard clinical care, and one would expect that inability to understand these languages does not preclude clinical care.

RESPONSE: This exclusion criterion was added because we do not have the ability to translate the clinical trial consent form accurately into other languages.

There is another ethical issue/potential risk with this procedure that is not discussed. A potential organ for life-saving heart transplant is diverted for a treatment that has other surgical options. This should be discussed and potentially be part of the informed consent. Furthermore, donor selection is not discussed in detail, could these donors have suboptimal cardiac function and not suitable for conventional heart transplant?

RESPONSE: We agree that donor selection is important and needs to be discussed. We also agree that donors with suboptimal cardiac function and not suitable for conventional transplant would be ideal. We added the following information to the discussion: “Partial heart transplantation can be performed using donor hearts with poor ventricular function and slow progression to donation after cardiac death. This should ameliorate donor heart utilization and avoid both primary orthotopic heart transplantation in children with unrepairable heart valve dysfunction and progression of these children to end-stage heart failure.” We also cited a recent review that we wrote about this very important topic (Sherard et al. Partial heart transplantation can ameliorate donor organ utilization. J Card Surg . 2022 Oct 19. doi: 10.1111/jocs.17050. Online ahead of print.).

It may be after this submission, but there has been a clinical case described as “first partial heart transplant” from Duke University in the news lately. Citation of that would be important for complete reference of prior work.

RESPONSE: this case is not yet published in the scientific literature.

Lower levels of immunosuppression are proposed as a possibility after first year, a description of such protocol is important for completeness.

RESPONSE: This is beyond the scope of the current clinical trial. Therefore, the reference to lower levels of immunosuppression was deleted.

Reviewer #2: This study addresses an interesting topic. It is well detailed and may lead to interesting results. Some comments follow.

1. The sample size is rather small. It is necessary to specify the power of the study. Similarly, the fact that it is a nonrandomized single-center study may strongly limit its practical usefulness. Indeed, my main concern is about how general the obtained results would be. It is difficult to understand why such a small sample size is aimed to be collected.

RESPONSE: The reason for the small sample size is the cost of the operation. Partial heart transplantation involves procurement of the donor heart using jet airplane transport in order to minimize the ischemia time. Therefore a larger number of patients for this pilot trial would be prohibitive.

2. Missing data management needs a better discussion. Missing data could be completely-at-random, at-random, not-at-random. Sensitivity analysis should be planned to avoid misleading inference whenever complete-case analysis is performed.

RESPONSE: We agree. The following paragraph was inserted in the data management methods section: “Missing data will be addressed by omission or analysis as appropriate. Sensitivity analysis will be planned to avoid misleading inference when complete-case analysis is performed.”

3. The data analysis is based on descriptive statistics only. This strongly limits the project. If research questions cannot be tested, if inference cannot be performed, the study simply describes a specific sample, that may not be representative of a larger population. Which general info do you expect to get from a simple descriptive analysis? Cause-effect relationships cannot be investigated, nor any characterization of the outcomes could be discussed. The data analysis is not sufficient to provide informative results. I strongly suggest to plan a more detailed and extensive statistical analysis, based on a larger sample. Statistical inference must be guranteed.

RESPONSE: We agree that a more detailed extensive statistical analysis based on a larger sample would be helpful. We are planning this as the next step once funding for can be secured, either for insurance companies that already fund all expenses for conventional heart transplants or via a grant. The following sentence was added to the conclusion: “In the future, extensive statistical analysis based on a larger sample will be necessary to further evaluate partial heart transplantation.”

Attachments
Attachment
Submitted filename: Response to Reviewers.docx
Decision Letter - Jaimin R. Trivedi, Editor

Partial Heart Transplantation for Severe Pediatric Semilunar Valve Dysfunction: A Clinical Trial Protocol

PONE-D-22-23111R1

Dear Dr. Rajab,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Jaimin R. Trivedi, MBBS, MPH

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does the manuscript provide a valid rationale for the proposed study, with clearly identified and justified research questions?

The research question outlined is expected to address a valid academic problem or topic and contribute to the base of knowledge in the field.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Is the protocol technically sound and planned in a manner that will lead to a meaningful outcome and allow testing the stated hypotheses?

The manuscript should describe the methods in sufficient detail to prevent undisclosed flexibility in the experimental procedure or analysis pipeline, including sufficient outcome-neutral conditions (e.g. necessary controls, absence of floor or ceiling effects) to test the proposed hypotheses and a statistical power analysis where applicable. As there may be aspects of the methodology and analysis which can only be refined once the work is undertaken, authors should outline potential assumptions and explicitly describe what aspects of the proposed analyses, if any, are exploratory.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Is the methodology feasible and described in sufficient detail to allow the work to be replicable?

Descriptions of methods and materials in the protocol should be reported in sufficient detail for another researcher to reproduce all experiments and analyses. The protocol should describe the appropriate controls, sample size calculations, and replication needed to ensure that the data are robust and reproducible.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors described where all data underlying the findings will be made available when the study is complete?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception, at the time of publication. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above and, if applicable, provide comments about issues authors must address before this protocol can be accepted for publication. You may also include additional comments for the author, including concerns about research or publication ethics.

You may also provide optional suggestions and comments to authors that they might find helpful in planning their study.

(Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Authors have responded to the comments adequately and made appropriate changes. This manuscript is well written.

Reviewer #2: All my comments are properly addressed. I believe this work is ready to be published. It will be a starting point for further analyses on the topic.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

Formally Accepted
Acceptance Letter - Jaimin R. Trivedi, Editor

PONE-D-22-23111R1

Partial Heart Transplantation for Pediatric Heart Valve Dysfunction: A Clinical Trial Protocol

Dear Dr. Rajab:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Jaimin R. Trivedi

Academic Editor

PLOS ONE

Open letter on the publication of peer review reports

PLOS recognizes the benefits of transparency in the peer review process. Therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. Reviewers remain anonymous, unless they choose to reveal their names.

We encourage other journals to join us in this initiative. We hope that our action inspires the community, including researchers, research funders, and research institutions, to recognize the benefits of published peer review reports for all parts of the research system.

Learn more at ASAPbio .